HELEN HESLOP to Immunophenotyping
This is a "connection" page, showing publications HELEN HESLOP has written about Immunophenotyping.
Connection Strength
0.456
-
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
Score: 0.072
-
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
Score: 0.046
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.037
-
Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. Cytotherapy. 2018 09; 20(9):1182-1190.
Score: 0.033
-
Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32.
Score: 0.032
-
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
Score: 0.031
-
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
Score: 0.028
-
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
Score: 0.025
-
Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7.
Score: 0.022
-
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013 Jan 01; 19(1):106-17.
Score: 0.022
-
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
Score: 0.020
-
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
Score: 0.019
-
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
Score: 0.017
-
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
Score: 0.017
-
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
Score: 0.015
-
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
Score: 0.014
-
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
Score: 0.007